In Regard to Vaidya et al.

Leukemia Group B 9343, which showed that locoregional recurrence continues to occur beyond 5 years (7). Furthermore, when compared with the initial results (5), the updated results of TARGIT-A (4) demonstrate a much higher increase in the rate of local recurrences for PBI (23 vs 6) compared with external beam radiotherapy group (11 vs 5). Further, we disagree with the authors (1) that this short-term follow-up can be used to report and conclude about the rates of secondary cancers (8). Finally, the authors claimed that the experimental arm had less cardiovascular toxicity (1), whereas the total number of patients in both groups was very low (2 vs 8), and because the data for left-sided cancers was not separately presented in any of the TARGIT-Aerelated publications, nor even the times of the cardiac deaths, their analysis of cardiovascular disease is misleading (4). It seems that only “time” will resolve the “clash of the titans”dhopefully not at the expense of our patients. Until the publication of final long-term results, we recommend restraint before implementing this technique outside of clinical trials.